Plain-English translation of NCT05827796 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called combined with standard chemotherapy medicines (paclitaxel and ) for people with advanced pancreatic cancer. Some participants will receive the medication with just chemotherapy, while others will also receive an additional immunotherapy drug called . The study aims to find the right dose of this treatment and understand how well it works and how safe it is.
Pancreatic cancer is very difficult to treat, and people with advanced disease need better treatment options. This trial is exploring whether this medication can help improve outcomes when combined with existing chemotherapy drugs, potentially offering a new approach for patients who haven't been treated yet.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of two treatment groups. Both groups receive oral medication () once daily by mouth, plus intravenous chemotherapy infusions twice during each 21-day cycle. One group receives chemotherapy alone, and the other group also receives an additional immunotherapy infusion. The study has two phases: first, researchers will test different doses to find the safest and most effective dose, then expand to treat more patients at that dose. You will have regular clinic visits, blood tests, and imaging scans to monitor how you are responding and check for side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China